We invite you to participate in the 23rd Transporter- and Barrier – Days taking place in Bad Herrenalb close to Karlsruhe, Germany, from May 21st to May 23rd, 2024. 


Subjects of this conference are membrane transport proteins in barrier organs, drug transport and drug delivery across biological membranes, screening models such as MCDK, Caco-2 cells, blood brain barrier cells, skin cells, hepatocytes and others as well as phospholipids in drug delivery. Please forward this message also to colleagues in your department. This conference might also be of special interest for PhD students to get in contact with participating colleagues from the pharma industry.  


Please register and submit an abstract for poster or oral presentation until Monday, May 6th 2024.  Registration fee is 300,- € covering 2 nights with complete room and board. In case of questions please call +49-6221-548336 or send an email to transportertage@googlemail.com


Herrenalber Transportertage 



We thank our sponsors : 

Preliminary Program

 



to be continued   


----------------------------------------------------------------------------------------------------------------------------------------------

Previous Topics of this Conference


•       Nanoparticles targeting solute carriers to cross the blood-brain barrier

•       Targeting of hepatocytes using a virus-mimetic nanocarrier

•       Brain regional drug distribution: relevance to Alzheimer’s disease treatment"

•       New Concepts of Pathogenesis and Therapy of Colitis Ulcerosa

•       OCTN1 and COPD - Is there a role for drug transporters in pulmonary disease

•       Recent attempts to surpass the BBB to treat brain disorders

•       Nanoparticle-bound doxorubicin for chemo-therapy of glioblastoma: Update on clinical trials

•       Anti-HIV and anti-HCV drugs inhibit p-glycoprotein efflux activity in Caco-2 cells and precision-cut rat and
  human intestinal slices

•       Are PLGA-based glutathione-modified nanoparticles sufficient to cross the blood-brain barrier?

•       Assessing the interaction of micro-tumors with cellular barriers in a scalable microfluidic in vitro model

•       Availability, Affinity and Avidity: Optimising Transcytosis Properties of Central Nervous System Delivery
  Systems using Computational Approaches

•       Bacteria-derived vesicles show low cytotoxicity but inherent antimicrobial activity against model pathogens

•       Cell Specific Effects and Mechanisms Mediated by 1, 25-dihydroxyvitamine D3 in the Protection of Alveolar-
  capillary Barrier

•       Cell-free transport protein expression

•       Changes of tricellular tight junction proteins in Crohn’s disease

•       Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of
   liraglutide

•       Combinational Nano-formulation for Increasing Therapeutic Efficacy by Targeting ABC Transporters in Cell-
  based Models

•       Development and testing of a CNS-penetrating translationally relevant TRAIl-variant

•       Efficiently targeting drug efflux through modulation of p-glycoprotein activity by small molecules: Design,
  Synthesis biological and computational study.

•       Elucidation of possible distinct digoxin-binding sites within the substrate-binding pocket of P-glycoprotein

•       Engineered Protein Capsules as drug delivery platform for treatment of CNS diseases

•       Establishment and validation of a viable in vitro skin model from different species for the evaluation of
  cutaneous diseases

•       Exploring the role of the constrictions and the central histidine in Formate-nitrate-transporters

•       From human induced pluripotent stem cell to barrier-building endothelial cells - Using a realistic model of the
  blood-brain barrier for the identification of essential nanoparticle   characteristics as drug delivery systems

•       Functional characterization of human intestinal ABC and SLC transport proteins in overexpression models
  and ex vivo intestinal tissue segments

•       Hypergravity on Brain Blood Barrier opening : benefit or alteration ?

•       Imitating Lipoproteins as Drug Delivery System - Apolipoprotein E-modified Lipid Nanoparticles

•       Impact of intestinal and renal membrane transporter ABCB1 gene polymorphisms on the pharmacokinetics
  of digoxin in healthy Caucasian subjects

•       In vitro tools to investigate creatine transport inhibition

•       Investigation of apical drug transporter activity using ex vivo porcine intestine to facilitate identification of
  potential drug-drug-interactions at an early state of drug development

•       L-type amino acid transporter 1 utilizing prodrugs: promising approach to targeted brain delivery of CNS
  drugs

•       Measurement of intracellular unbound drug concentrations

•       Monitoring Penetration of Target Specific Active Ingredients by Using a Depth Profiling Approach

•       Monocarboxylate Transporter 8 Expression Profile: Constant Protein Abundance in Barriers of the CNS
  versus Developmental Decline of Neuronal Expression

•       Multidrug resistance protein 4 (MRP4) excretes paracetamol glutathione and cysteine conjugates from liver
  and kidney

•       Novel Developments and Challenges of Blood-Brain Barrier in vitro Models

•       Organ-on-a-Chip technology: 3D human blood-brain-barrier, kidney, and gut models for high-throughput
  barrier and transport measurements

•       Peptide conjugation of glycopeptide antibiotics leads to conjugates that overcome all types of resistance

•       P-gp inhibition in human stem-cell derived brain endothelial cells by Group B Streptococcus

•       PLGA nanoparticles for oral drug delivery: Influence of polymer end groups and particle size on permeability
  in the Caco-2 model

•       Self-assembled α-tocopherol transfer protein nanoparticles promote vitamin E delivery across an endothelial
  barrier

•       SLC26A9 as an alternative epithelial Cl- channel in muco-obstructive lung diseases

•       Species differences of hNTCP and mNtcp in transport characteristics and the inhibitory potential of selected
  drugs and pesticides

•       Suggestions for improved experimental design of small molecule transfer and transport studies with two
  compartment cell culture models

•       The Aη peptide Impairs LRP-1 dependent clearance of Amyloid β at the BBB

•       The blood-brain barrier in obesity – tracing leptin through the endothelial cell

•       The blood-saliva barrier: Establishment of in vitro models of the human salivary gland and further
  characterization of isolated colonies.

•       The in vitro evaluation of inhibitory potency of anti-HIV and anti-HCV drugs on P-glycoprotein; impact on
  digoxin intestinal absorption

•       The role of LRP1 in stroke therapy with Actilyse

•       Transport of glucose-derived ß-carboline alkaloids across the Caco-2 cell monolayer

•       Transport of nucleoside-derived antivirals across the rat and human placental barrier: roles of nucleoside
  and ATP-binding cassette drug efflux transporters